Mohammed Al-Jumayli, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

MohammedAmeir Abdul KarimAl-JumayliMD

Oncology Tampa, FL

Hematologic Oncology

Assistan professor, Oncology Sciences,USF

Overview of Dr. Al-Jumayli

Dr. Mohammed Al-Jumayli, MD is an oncologist in Tampa, Florida. He is currently licensed to practice medicine in Florida, Kansas, and Pennsylvania. He is affiliated with H. Lee Moffitt Cancer Center and Research Institute.

Education & Training

  • Capital Health System - Fuld CampusResidency, Internal Medicine, 2013 - 2016
  • University of Al-Mustansiriyah College of Medicine
    University of Al-Mustansiriyah College of MedicineClass of 1999

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2020 - 2022
  • KS State Medical License
    KS State Medical License 2017 - 2020
  • PA State Medical License
    PA State Medical License 2015 - 2015
  • MA State Medical License
    MA State Medical License 2015 - 2015
  • NJ State Medical License
    NJ State Medical License 2014 - 2018
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Geriatric Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • ASCO Annual Meeting Merit Awards, Conquer Cancer ASCO, Conquer Cancer foundation, 2020

Publications & Presentations

PubMed

Journal Articles

  • Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study  
    A. Saeed, H. Hildebrand, R. Park, M. Al-Jumayli, S. Abbasi, T. Melancon, A. Saeed, R. Al-Rajabi, A. Kasi, J. Baranda, S. Williamson, W. I Sun, Journal of Clinical Medicine, 8/16/2020
  • Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma  
    Robin Park, Fariha Eshrat, Mohammed Al-Jumayli, Azhar Saeed, Anwaar Saeed, Multidisciplinary Digital Publishing Institute, 7/11/2020
  • Association of Serrated polyps with extracolonic malignancies.  
    Mohammed AL-Jumayli,MD,D. Goldsmith, J Rogart,MD, The American Journal of Surgical Pathology
  • Join now to see all

Abstracts/Posters

  • Neoadjuvant cisplatin based therapy in bladder cancer: Is less enough?
    Saqib Abbasi, Mohammed Al-Jumayli, Hannah Hildebrand, Elizabeth Marie Wulff-Burchfield, Eugene K Lee, John A Taylor, Jeffrey Holzbeierlein, Grace Martin, Rahul Atul Pa..., Journal of Clinical Oncology, Chicago,USA, 6/1/2020
  • Clinical Outcomes of different management modalities of Anaplastic Thyroid Cancer: A single Center Experience
    Mohammed Al-Jumayli, Hameem Kawsar, Prakash Neupane, International Journal of Radiation Oncology• Biology• Physics, Arizona, USA, 2/24/2020
  • Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC).
    Mohammed Al-Jumayli, Hannah Hildebrand, Saqib Abbasi, Anup Kasi, Anwaar Saeed, American Society of Clinical Oncolog GI , JCO, US, 1/27/2020
  • Join now to see all

Lectures

  • Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC). 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020

Hospital Affiliations